Nippon Chemiphar Co., Ltd. (NIPPON CHEMIPHAR CO) aktie

Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development. In addition, the company develops NC-2700, a URAT1 inhibitor for hyperuricemia, guot currently under preclinical development; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety currently under Phase 1 development; DFP-17729, a cancer microenvironment improving agent far pancreatic cancer currently under phase 2 development; and DE-P-14323, an anti-cancer agent for non-small cell lung cancer currently under phase 2 development. Further, it is involved in the development of Soleton, an analgesic and anti-inflammatory drug; and Calvan, a blocker for huntington's disease currently under phase 2 development. Additionally, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various types of creams. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was incorporated in 1950 and is headquartered in Tokyo, Japan.